72-kDa and 92-kDa gelatinases in saliva of patients with human immunodeficiency virus infection.
Human immunodeficiency virus (HIV) infection has been associated with periodontal diseases in HIV-seropositive patients. In periodontal diseases, matrix metalloproteinases (MMPs) may play key roles in the extracellular matrix, basement membrane, serpin degradation, and modification of cytokine action. We characterized the 72 kDa type IV collagenase (gelatinase A, MMP-2) and 92 kDa type IV collagenase (gelatinase B, MMP-9) in the saliva of HIV-seropositive patients and seronegative healthy controls by activity measurements and quantitative immunoblotting. Immunoblot analysis with specific antibodies against MMP-2 and MMP-9 and their tissue inhibitors (TIMP-1, TIMP-2) disclosed that, independent of the phase of the patients' HIV infection, their salivary samples contained higher amounts of MMP-2 and MMP-9 immunoreactivities in pro- and active forms and the TIMP-1 and TIMP-2 inhibitors than did the control samples. Healthy control saliva contained only slight immunoreactivities for gelatinases and TIMPs. However, as judged by the studied clinical and microbiologic indicators, HIV-seropositive patients showed only a slight tendency to develop periodontitis. Overall, an increased amount of gelatinases in saliva may reflect increased host response and defense activities in HIV infection.
Department of Periodontology, Institute of Dentistry, University of Helsinki, Finland.
L
L
Mellanen
T
T
Salo
T
T
Ingman
Y T
YT
Konttinen
J
J
Lähdevirta
T
T
Sorsa
D000328:Adult; D000368:Aged; D001485:Basement Membrane / Q000201:enzymology; D016022:Case-Control Studies; D017364:Collagenases / Q000032:analysis*; D016207:Cytokines / Q000502:physiology; D005109:Extracellular Matrix / Q000201:enzymology; D005260:Female; D018093:Gelatinases / Q000032:analysis*; D015658:HIV Infections / Q000150:complications / Q000201:enzymology*; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications / Q000201:enzymology; D006801:Humans; D015151:Immunoblotting; D008297:Male; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D008666:Metalloendopeptidases / Q000032:analysis*; D008875:Middle Aged; D010510:Periodontal Diseases / Q000150:complications / Q000201:enzymology; D010518:Periodontitis / Q000150:complications / Q000201:enzymology; D011480:Protease Inhibitors / Q000032:analysis; D012463:Saliva / Q000201:enzymology*; D012471:Salivary Proteins and Peptides / Q000032:analysis*; D015842:Serine Proteinase Inhibitors / Q000378:metabolism; D015843:Serpins / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000032:analysis
D016207:Cytokines; D011480:Protease Inhibitors; D012471:Salivary Proteins and Peptides; D015842:Serine Proteinase Inhibitors; D015843:Serpins; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D017364:Collagenases; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9